Broadening horizons in health technology
That is the title of an interview with me in The Evidence Base out today with the subtitle Introducing generalized cost effectiveness analysis for a comprehensive value assessment. Below is an excerpt:
What is this paper about? What is new in this paper?
Our recent publication presents a comprehensive framework for evaluating the societal value of health technologies, known as the generalized cost-effectiveness analysis (GCEA) model. Unlike traditional cost-effectiveness analysis, which focuses primarily on healthcare sector costs and direct patient benefits, GCEA introduces a broader range of value elements from a societal perspective. These include aspects like patient and caregiver spillover effects, productivity impacts, and community benefits. GCEA aims to expand and update previous efforts—such as the ISPOR Value Flower and Second Panel on Cost Effectiveness in Health and Medicine—capturing additional elements like dynamic net health system costs and incorporating recent methodological advances such as generalized and risk-adjusted cost effectiveness (GRACE) and distributional cost-effectiveness analysis (DCEA).
The paper also offers readers a user-friendly guide for applying this GCEA framework in health technology assessments (HTAs). It classifies broader societal benefits into four fundamental categories:
– Uncertainty
– Dynamics
– Beneficiaries
– Additional value elements
Perhaps more importantly, each value element contains its own section with a definition, best practice methodology guide, simple examples, and useful references to help researchers better estimate each of these value elements in practice.
You can read the whole interview here.
